With Microsoft Deal, Novartis Continues to Focus its Future Development on AI, Machine Learning BioSpace

Swiss pharma giant Novartis has partnered with tech giant Microsoft and launched its Novartis AI innovation lab as a means to leverage data and artificial intelligence to transform drug discovery and development. The new Novartis AI lab aims to significantly bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide, the company announced Monday. As part of the strategic collaboration between the two companies, Novartis and Microsoft have committed to a multi-year research and development effort with a focus on AI empowerment and AI exploration. With AI empowerment, Novartis said the goal is for every employee in the lab to have the AI program on their computer. Using Novartis' datasets and Microsoft's AI solutions, the company said the lab will create new AI models and applications that can augment their discovery and development capabilities.